As the number of actionable, prognostic and therapeutic biomarkers increases, it’s critical to find ways to maximize the ability to match patients with appropriate molecular treatment regimens. Find out more about how Comprehensive Genomic Profiling (CGP) is being applied to deal with the complexity of Non-Small Cell Lung Cancer (NSCLC) and hear from two industry leading experts on how they incorporate CGP into their labs, and their practices.
Watch now and learn more:
Illumina update on their IVD road map
Dr. Phil Febbo, Chief Medical Officer, Illumina
The impact of Comprehensive Genomic Profiling
Dr. Anke Homann, Associate Director of Medical Affairs, Illumina
A day in the life of a pathologist using Comprehensive Genomic Profiling
Dr. Henrik Hager, Consultant Pathology, Vejle Hospital
Dealing with complexity through Comprehensive Genomic Profiling
Prof. Ed Schuuring, Professor of Molecular Oncological Pathology, University Medical CenterGroningen
Your email address is never shared with third parties.